Skip to main content

Table 1 Characteristics of 33 relapsed lung ADC patients with SCLC transition

From: Pathological transition as the arising mechanism for drug resistance in lung cancer

Patient ID Gender Age Smoking status Therapy 1st biopsya 2nd biopsyb References
Pathological status Mutation status Pathological status Mutation status
1 M 54 NA TKI ADC EGFR 19 del SCLC EGFR 19 del [32]
2 F 56 NA TKI ADC EGFR 19 del SCLC EGFR 19 del [32]
3 F 61 NA TKI ADC EGFR 19 del SCLC EGFR 19 del [32]
4 F 72 N Gef ADC EGFR 19 del SCLC EGFR 19 del [91]
5 F 46 N Erl ADC EGFR 19 del SCLC EGFR 19 del [92]
6 F 52 N Erl ADC EGFR 19 del SCLC EGFR 19 del [93]
7 M 80 N Ico ADC EGFR 19 del SCLC EGFR 19 del [94]
8 F 63 N Erl ADC EGFR 19 del SCLC EGFR 19 del [95]
9 M 46 Y Gef ADC EGFR 19 del SCLC EGFR 19 del [96]
10 M 49 Y Erl ADC EGFR 19 del and FGFR3 exon 17 deletion SCLC EGFR 19 del and FGFR3 exon 17 deletion [97]
11 F 60 N Gef ADC EGFR 19 del SCLC EGFR 19 del [98]
12 M 65 N Afa ADC EGFR 19 del SCLC EGFR 19 del [99]
13 F 37 N Gef ADC EGFR 19 del SCLC EGFR 19 del + T790M [100]
14 F 42 N Erl ADC EGFR 19 del SCLC EGFR 19 del + T790M [101]
15 F 49 N Gef ADC EGFR 19 del SCLC NA [102]
16 M 41 Y Gef ADC EGFR 19 del SCLC + SCC NA [61]
17 M 74 Y Gef ADC EGFR 19 del SCLC WT [103]
18 F 48 NA TKI ADC EGFR L858R SCLC EGFR L858R [32]
19 F 67 NA TKI ADC EGFR L858R SCLC EGFR L858R [32]
20 F 72 N Gef ADC EGFR L858R SCLC EGFR L858R [104]
21 M 46 N Gef ADC EGFR L858R SCLC EGFR L858R [105]
22 M 49 Y Gef ADC EGFR L858R SCLC EGFR L858R [106]
23 F 65 N Gef ADC EGFR L858R SCLC EGFR L858R [107]
24 M 73 NA Gef ADC EGFR L858R SCLC EGFR L858R [108]
25 F 40 NA TKI ADC EGFR L858R SCLC EGFR L858R and PIK3CA [32]
26 M 38 N Erl ADC EGFR L858R SCLC NA [109]
27 M 72 Y Crizo ADC ALK SCLC ALK [33]
28 M 67 N Alec ADC ALK SCLC ALK [34]
29 F 72 N Gef ADC WT SCLC NA [35]
30 M 61 N TKI ADC NA SCLC EGFR 19 del [110]
31 F 46 N Gef ADC NA SCLC EGFR 19 del [111]
32 F 45 N Erl- Gef ADC NA SCLC EGFR 19 del [31]
33 F 73 N Gef ADC NA SCLC EGFR L858R [104]
  1. Y yes, N no, NA not available, M male, F female, ADC adenocarcinoma, SCC squamous cell carcinoma, SCLC small cell lung cancer, TKI tyrosine kinase inhibitor, Gef gefitinib, Erl erlotinib, Ico icotinib, Afa afatinib, Crizo crizotinib, Alec alectinib, EGFR epidermal growth factor receptor, EGFR 19 del EGFR exon 19 deletion, ALK anaplastic lymphoma kinase, WT wild-type
  2. a1st biopsy: the first biopsy
  3. b2nd biopsy: the second biopsy
Back to article page

Cancer Communications

ISSN: 2523-3548

Contact us